A smarter GLP-1 solution, built to scale
GLP-1 claims are surging. Embla gives you a clinically proven, fully managed alternative that reduces GLP-1 use by 66% while improving outcomes. The result is lower costs, higher member value, and fewer long-term claims.
GLP-1 demand is here, and growing
Health plans are under pressure to meet member demand without blowing the budget. Embla helps you do both.
Why conventional GLP-1 coverage falls short
Full-dose prescriptions can quickly overwhelm your medical trend.
Without coaching, members often regain weight or stop treatment early.
Most solutions don’t taper, driving long-term costs and dependency.
A proven, cost-controlled GLP-1 program
We combine low-dose GLP-1s with ACT-based coaching and tapering, delivering up to 85% better outcomes than meds alone. Fully digital. No complicated onboarding. Live in 7 days.
Boosted engagement
1:1 coaching, digital tracking, and flexible care plan, without extra work for your team.
Improved outcomes
Members see improvements in weight, energy, mental health, and metabolic risk.
Lower claims
Our low-dose approach reduces both pharmacy and chronic condition costs.
A strategic edge
Stand out with a high-demand solution that meets member needs and controls trend, all with predictable, under-$500 PEPM pricing.
Real world-results.
Real-world savings.
We keep employees on the lowest effective dose — saving thousands per person.
Embla members lose significantly more weight than users of GLP-1s without coaching 40–85% more.
Backed by data: lower A1c, blood pressure, cholesterol, and long-term obesity-related costs.
Easy to offer, built to scale
1. Meet with us
We align on population needs, goals, and rollout strategy.
2. We take care of everything
Embla manages onboarding, prescriptions, coaching, and reporting.
3. Go live in 7 days
No plan disruption. No integration. No lift for your team.
Backed by real-world data from over 2,000 members
Our TRIM study, presented at ECO2025, proves our approach works:
16.7% avg. weight loss in 12 months
Only 34–36% of the full semaglutide dose used
100% of members with a week-64 weight lost >5%
85.3% lost >10%
No difference in outcomes across BMI groups
Easy to launch. Easy to love.
Embla is fully managed and plug-and-play. No complicated onboarding. No surprises.
Ready to offer a smarter GLP-1 benefit?
Let’s talk about how Embla can help you reduce GLP-1 spend and raise the standard of care.